Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : COVID-19 shots could reach first Americans by mid-December, top health official says

11/22/2020 | 02:21pm EST

(Outdoor restaurant and bar service halted in Los Angeles County; U.S. hospitalizations rise nearly 50%)

Nov 22 (Reuters) - U.S. healthcare workers and others recommended for the nation's first COVID-19 inoculations could start getting shots within a day or two of regulatory consent next month, a top official of the government's vaccine development effort said on Sunday.

Some 70% of the U.S. population of 330 million would need to be inoculated to achieve "herd" immunity from the virus, a goal the country could achieve by May, according to Dr. Moncef Slaoui, chief scientific adviser for "Operation Warp Speed."

Slaoui said the U.S. Food and Drug Administration (FDA) would likely grant approval in mid-December for distribution of the vaccine produced by Pfizer Inc and German partner BioNTech, launching the largest inoculation campaign in U.S. history.

The FDA's outside advisers are slated to meet on Dec. 10 to review Pfizer's emergency-use application for its vaccine, which the company said was found to be 95% effective against infection from the highly contagious respiratory virus.

A second pharmaceutical company, Moderna Inc, is expected to seek separate approval later in December for its COVID-19 vaccine.

Appearing on several network news shows on Sunday morning, Slaoui sketched out a timeline for getting the initial doses of the Pfizer vaccine from FDA authorization into the arms of those who will be first in line to receive it.

"Within 24 hours from the approval, the vaccine will be moving and located in the areas where each state will have told us where they want the vaccine doses," Slaoui told NBC's "Meet the Press."

"So I would expect, maybe on day two after approval on the 11th or 12th of December, hopefully the first people will be immunized across the United States," he said on CNN's "State of the Union" program.

Once emergency-use approval is granted, Slaoui said, the U.S. Centers for Disease Control and Prevention (CDC) and an advisory panel on immunization practices will recommend who should receive the vaccine first.

Slaoui said they are likely to include doctors, nurses and "front-line" emergency medical personnel, as well as individuals considered to be at the highest risk of severe illness and death from the virus, such as the elderly.

Public health authorities in each state will be responsible for administering the vaccine roll-out, with the first doses distributed to the states proportionate to their populations, he said.

President-elect Joe Biden and his advisers have voiced concern that President Donald Trump's continued refusal to share vaccine data and distribution plans with Biden's transition team could cause delays after the next administration takes office on Jan. 20.

Slaoui said he hoped for a smooth hand-off and did not expect the vaccination effort to be derailed.

SURGING CASES AND SUPER-SPREADERS

Details on the timeline emerged as coronavirus infections rage further out of control across the country, besieging hospitals with mounting numbers of COVID-19 patients.

The crisis has prompted state and local government leaders nationwide to re-impose restrictions on social and economic life in hopes of breaking the transmission cycle.

On Sunday, Los Angeles County health officials announced that outdoor service at restaurants, bars and wineries would be banned for at least the next three weeks as the daily number of new coronavirus cases surpassed a five-day average of 4,000.

The new measure, restricting eateries in and around the nation's second-largest city to takeout and deliveries only for the first time since late May, goes into effect on Wednesday.

Health experts worry that the surge will only worsen, as millions of Americans prepared to travel and congregate in family groups for Thanksgiving celebrations, despite warnings that they stay home to avoid spreading the disease.

Many people were scrambling to get tested before Thursday's holiday, leading to long lines at screening sites in New York City and elsewhere. Most pharmacies offering COVID-19 tests in suburban Chicago were fully booked.

"I believe COVID rates will increase just as I believe most New Yorkers will put on weight," New York Governor Andrew Cuomo lamented at a Sunday press conference.

Cuomo also said the city was investigating reports of an ultra-Orthodox Jewish wedding that drew some 7,000 people to a reception in Brooklyn, video footage of which showed throngs of maskless guests celebrating shoulder to shoulder.

The United States surpassed 12 million COVID-19 cases on Saturday, as the nation's death toll climbed to more than 255,000 since the pandemic began. Coronavirus hospitalizations have increased nearly 50% over the past two weeks.

Reuters data showed the pace of new infections quickening, with nearly 1 million more cases documented over the past six days, compared with the eight days it took to get from 10 million to 11 million cases.

The epicenter of the U.S. pandemic has also shifted in recent weeks, with the Midwest and Rockies leading the nation in terms of rapidly escalating infections.

"It's not just in big cities, but it's in rural locations, small towns," Dr. Tom Inglesby, director of the Center for Health Security at Johns Hopkins University, said on "Fox News Sunday."

While the prospect of effective vaccines has brought new hope to a pandemic-weary nation, public distrust of inoculations runs high. In a recent Gallup poll, just 58% of Americans said they planned to get a COVID-19 vaccine, up from 50% in September.

(Reporting by Doina Chiacu; Additional reporting by Will Dunham; Writing by Lisa Shumaker and Steve Gorman; Editing by Daniel Wallis)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 3.37% 151.995 Delayed Quote.40.71%
PFIZER INC. 0.25% 37.39 Delayed Quote.1.28%
All news about MODERNA, INC.
03:29pMODERNA : Calgary company begins clinical trials for Canadian-made COVID vaccine..
AQ
02:54pPfizer working on booster shot to protect against COVID-19 variants
RE
01:46pJohnson & Johnson's Profit Is Boosted by Pharmaceuticals Business -- 2nd Upda..
DJ
01:29p44.3 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
RE
01:08pPFIZER : Can COVID-19 vaccines be mixed and matched?
AQ
12:48pGAVI seeks political support for COVAX as rich nations strike fresh vaccine d..
RE
12:40pJ&J 4Q sales rise despite pandemic, but charges cut profits
AQ
12:10pEU drugs agency says it is offering advice to makers of Russian vaccine
RE
12:02pSOCIALIZING AFTER THE VACCINE : Experts say shot won't offer "free pass" right a..
AQ
11:50aMODERNA : Canadians who have had COVID-19 should still get the vaccine, experts ..
AQ
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -120x
Yield 2020 -
Capitalization 58 169 M 58 169 M -
EV / Sales 2020 109x
EV / Sales 2021 5,05x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,93 $
Last Close Price 147,00 $
Spread / Highest target 25,9%
Spread / Average Target -6,17%
Spread / Lowest Target -53,1%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
SEAGEN INC.2.84%32 583
HANGZHOU TIGERMED CONSULTING CO.,LTD18.50%25 245